energetic paul hopper set to control virax?, page-3

"...The market appears to be digesting the news and generally positive."

Apt summary, maxter.

I think the announcement has some compelling implications for VHL's future:

. Positioning in lucrative cancer/multiple myeloma markets;

. Highly credentialled scientists and institutions now collaborating;

. Emergence of Paul Hopper as a key board and share register influence;

. Another runway to complement the Transgene/Novartis Co-X-GENE lung cancer platform.

And the Virax board is to be crammed with can-do adventure capitalists - Dr Wayne Millen, Dr Brendan de Kauwe and now Paul Hopper.

As for the IP review, the reviewer has been/is being delayed by paperwork issues.

Many records have been mislaid.

Scores of boxes need to be opened, the contents assembled and analyzed.

While the reviewer has been given a deadline, I sense we'll need to exercise more patience.

Meantime, shares are short of their recent $0.020 high.

MC still sub $9m.

Don't understand why.

Will buy more!